AU6543286A - Method of using bar1 for secreting foreign proteins - Google Patents

Method of using bar1 for secreting foreign proteins

Info

Publication number
AU6543286A
AU6543286A AU65432/86A AU6543286A AU6543286A AU 6543286 A AU6543286 A AU 6543286A AU 65432/86 A AU65432/86 A AU 65432/86A AU 6543286 A AU6543286 A AU 6543286A AU 6543286 A AU6543286 A AU 6543286A
Authority
AU
Australia
Prior art keywords
barl
promoter
fragment
gene
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65432/86A
Other languages
English (en)
Inventor
Vivian L. Mackay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU6543286A publication Critical patent/AU6543286A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU65432/86A 1985-10-25 1986-10-20 Method of using bar1 for secreting foreign proteins Abandoned AU6543286A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
US791305 1985-10-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU74003/91A Division AU676132B2 (en) 1985-10-25 1991-04-02 Method of using bar1 for secreting foreign proteins

Publications (1)

Publication Number Publication Date
AU6543286A true AU6543286A (en) 1987-05-19

Family

ID=25153298

Family Applications (2)

Application Number Title Priority Date Filing Date
AU65432/86A Abandoned AU6543286A (en) 1985-10-25 1986-10-20 Method of using bar1 for secreting foreign proteins
AU74003/91A Ceased AU676132B2 (en) 1985-10-25 1991-04-02 Method of using bar1 for secreting foreign proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU74003/91A Ceased AU676132B2 (en) 1985-10-25 1991-04-02 Method of using bar1 for secreting foreign proteins

Country Status (13)

Country Link
EP (1) EP0243465A1 (hu)
JP (1) JP2523562B2 (hu)
CN (1) CN1027179C (hu)
AU (2) AU6543286A (hu)
CA (1) CA1316133C (hu)
CZ (1) CZ284251B6 (hu)
DK (1) DK320287D0 (hu)
FI (1) FI872801A (hu)
HU (1) HU206897B (hu)
IE (1) IE63822B1 (hu)
SK (1) SK776486A3 (hu)
UA (1) UA41863C2 (hu)
WO (1) WO1987002670A1 (hu)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU590197B2 (en) * 1984-05-30 1989-11-02 Novo Nordisk A/S Insulin precursors, process for their preparation and process for preparing human insulin from such insulin precursors
AU633020B2 (en) * 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences
AU660172B2 (en) * 1987-10-02 1995-06-15 Zymogenetics Inc. BAR1 secretion signal

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
WO1991013971A1 (en) * 1990-03-13 1991-09-19 Hawaii Biotechnology Group, Inc. Neurospora expression system
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
NZ303162A (en) 1995-03-17 2000-01-28 Novo Nordisk As Enzyme preparations comprising an enzyme exhibiting endoglucanase activity appropriate for laundry compositions for textiles
CZ297338B6 (cs) 1996-03-01 2006-11-15 Novo Nordisk A/S Peptid potlacující chut k jídlu, farmaceutický prostredek jej obsahující a jeho pouzití
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
PT1257295E (pt) 2000-02-11 2009-07-16 Bayer Healthcare Llc Moléculas de tipo factor vii ou viia
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
EP1373493B1 (en) 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Coagulation factor vii derivative
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
HUP0500060A3 (en) 2001-09-27 2010-01-28 Novo Nordisk Healthcare Ag Human coagulation factor vii polypeptides
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
EP1926817A2 (en) 2005-09-14 2008-06-04 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
AU2007223880A1 (en) 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin and fibrinogen
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
ES2654387T3 (es) 2008-07-23 2018-02-13 Ambrx, Inc. Polipéptidos G-CSF bovinos modificados y sus usos
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
EP2406282A1 (en) 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
EP2454281B1 (en) 2009-07-17 2018-11-14 Omeros Corporation Masp isoforms as inhibitors of complement activation
CN102666570B (zh) 2009-12-01 2015-12-02 诺沃—诺迪斯克有限公司 新的肽基α-羟基甘氨酸α-酰胺化裂合酶
AU2010341516B2 (en) 2009-12-21 2014-01-16 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
EP2649178B8 (en) 2010-12-09 2017-08-30 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
EP2788478B1 (en) 2011-12-09 2017-08-23 Institut Pasteur Multiplex immuno screening assay
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
CA2861051C (en) 2012-02-09 2021-06-22 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
JP2015532307A (ja) 2012-10-15 2015-11-09 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 凝固因子ｖｉｉポリペプチド
JP2014128262A (ja) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd 接合能を持つ酵母細胞株のスクリーニング方法
CA3098910A1 (en) 2018-05-01 2019-11-07 Ambrx, Inc. A method for optimizing antibody expression
CN112789504A (zh) 2018-07-13 2021-05-11 瓦克特诊断有限责任公司 使用重组疟疾蛋白var2csa分离胎儿来源的循环细胞
US12049485B2 (en) 2018-09-11 2024-07-30 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
BR112021015832A2 (pt) 2019-02-12 2022-01-18 Ambrx Inc Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of using them
EP4136459A1 (en) 2020-04-13 2023-02-22 Abbott Laboratories Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024512775A (ja) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
CN115806889B (zh) * 2022-09-28 2024-06-11 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
JPS61247384A (ja) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド 酵母中でプラスミノ−ゲン活性化因子を発現する方法
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU590197B2 (en) * 1984-05-30 1989-11-02 Novo Nordisk A/S Insulin precursors, process for their preparation and process for preparing human insulin from such insulin precursors
AU660172B2 (en) * 1987-10-02 1995-06-15 Zymogenetics Inc. BAR1 secretion signal
AU633020B2 (en) * 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences

Also Published As

Publication number Publication date
HUT43624A (en) 1987-11-30
CA1316133C (en) 1993-04-13
DK320287A (da) 1987-06-23
CZ776486A3 (en) 1996-09-11
DK320287D0 (da) 1987-06-23
WO1987002670A1 (en) 1987-05-07
AU676132B2 (en) 1997-03-06
UA41863C2 (uk) 2001-10-15
FI872801A0 (fi) 1987-06-24
CN1027179C (zh) 1994-12-28
JP2523562B2 (ja) 1996-08-14
SK279041B6 (sk) 1998-06-03
IE862804L (en) 1987-04-25
HU206897B (en) 1993-01-28
CZ284251B6 (cs) 1998-10-14
JPS63501614A (ja) 1988-06-23
IE63822B1 (en) 1995-06-14
CN86107554A (zh) 1987-08-26
SK776486A3 (en) 1998-06-03
FI872801A (fi) 1987-06-24
AU7400391A (en) 1991-07-18
EP0243465A1 (en) 1987-11-04

Similar Documents

Publication Publication Date Title
CA1316133C (en) Method of using bar1 for secreting foreign proteins
CA1340772C (en) Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5037743A (en) BAR1 secretion signal
CA1340547C (en) Novel secretory leader sequences for yeasts
EP0123544A2 (en) Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor
CA2090969C (en) Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA2085308C (en) Dibasic endoprotease fused to endoplasmic reticulum retention signal and use thereof
US5612198A (en) Production of insulin-like growth factor-1 in methylotrophic yeast cells
EP0220689B1 (en) Method of using bar1 for secreting foreign proteins
US7198919B1 (en) Use of alpha factor sequences in yeast expression systems
JP3135550B2 (ja) 成熟異種タンパク質、特にヒルジン、の製造のための改良された酵母株、および対応するヒルジンの製造法
JP4180112B2 (ja) 酵母細胞におけるｎ末端を伸長されたタンパクの発現のためのベクター
EP0310137B1 (en) BAR1 secretion signal
US5879926A (en) Yeast strains for the production of mature heterologous proteins, especially hirudin
EP1097228B1 (en) Method of making proteins in transformed yeast cells
WO1991002057A1 (en) Polypeptide production in fungi